Inverse correlation between NKG2D expression on CD8+ T cells and the frequency of CD4+CD25+ regulatory T cells in patients with esophageal cancer

Diseases of the Esophagus

Volumn 22, Issue 1, 2009, Pages 49-54

  Osaki, T ^a   Saito, H ^a   Fukumoto, Y ^a   Yamada, Y ^a   Fukuda, K ^a   Tatebe, S ^a   Tsujitani, S ^a   Ikeguchi, M ^a  

^a TOTTORI UNIVERSITY   (Japan)

Author keywords

CD8+ T lymphocytes; Esophageal cancer; NKG2D; Regulatory T lymphocytes

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; CELL SURFACE RECEPTOR; INTERLEUKIN 2 RECEPTOR ALPHA; NATURAL KILLER CELL RECEPTOR NKG2D;

ADULT; ARTICLE; CANCER PATIENT; CANCER STAGING; CD4+ CD25+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; DATA ANALYSIS; DISEASE SEVERITY; ESOPHAGUS CANCER; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNE DEFICIENCY; LYMPH NODE METASTASIS; MALE; NATURAL KILLER CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION;

AGED; CD8-POSITIVE T-LYMPHOCYTES; ESOPHAGEAL NEOPLASMS; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHATIC METASTASIS; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY K; T-LYMPHOCYTES, REGULATORY;

EID: 58749088782     PISSN: 11208694     EISSN: 14422050     Source Type: Journal    
DOI: 10.1111/j.1442-2050.2008.00855.x     Document Type: Article

References (32)

1. Parkin D M. Global cancer statistics in the year 2000. Lancet Oncol 2001; 2: 533-43.
2. Wu P C, Posner M C. The role of surgery in the management of oesophageal cancer. Lancet Oncol 2003; 4: 481-8.
3. O'Sullivan G C, Corbett A R, Shanahan F, Collins J K. Regional immunosuppression in esophageal squamous cancer: Evidence from functional studies with matched lymph nodes. J Immunol 1996; 157: 4717-20.
4. O'Mahony A M, O'Sullivan G C, O'Connell J, Cotter T G, Collins J K. An immune suppressive factor derived from esophageal squamous carcinoma induces apoptosis in normal and transformed cells of lymphoid lineage. J Immunol 1993; 151: 4847-56.
5. Sakaguchi S. Regulatory T cells: Key controllers of immunologic self-tolerance. Cell 2000; 101: 455-8.
6. Shevach E M. CD4+ CD25+ suppressor T cells: More questions than answers. Nat Rev Immunol 2002; 2: 389-400.
7. Woo E Y, Chu C S, Goletz T J et al. Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res 2001; 61: 4766-72.
8. Woo E Y, Yeh H, Chu C S et al. Cutting edge: Regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation. J Immunol 2002; 168: 4272-6.
9. Liyanage U K, Moore T T, Joo H G et al. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol 2002; 169: 2756-61.
10. Glienke J, Sobanov Y, Brostjan C et al. The genomic organization of NKG2C, E, F, and D receptor genes in the human natural killer gene complex. Immunogenetics 1998; 48: 163-73.
11. Raulet D H. Roles of the NKG2D immunoreceptor and its ligands. Nat Rev Immunol 2003; 3: 781-90.
12. Watzl C. The NKG2D receptor and its ligands-recognition beyond the 'missing self '? Microbes Infect 2003; 5: 31-7.
13. Vivier E, Tomasello E, Paul P. Lymphocyte activation via NKG2D: Towards a new paradigm in immune recognition? Curr Opin Immunol 2002; 14: 306-11.
14. Bauer S, Groh V, Wu J et al. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 1999; 285: 727-9.
15. Cerwenka A, Bakker A B, McClanahan T et al. Retinoic acid early inducible genes define a ligand family for the activating NKG2D receptor in mice. Immunity 2000; 12: 721-7.
16. Diefenbach A, Jamieson A M, Liu S D, Shastri N, Raulet D H. Ligands for the murine NKG2D receptor: Expression by tumor cells and activation of NK cells and macrophages. Nat Immunol 2000; 1: 119-26.
17. Jamieson A M, Diefenbach A, McMahon C W, Xiong N, Carlyle J R, Raulet D H. The role of the NKG2D immunoreceptor in immune cell activation and natural killing. Immunity 2002; 17: 19-29.
18. Groh V, Wu J, Yee C, Spies T. Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature 2002; 419: 734-8.
19. Salih H R, Antropius H, Gieseke F et al. Functional expression and release of ligands for the activating immunoreceptor NKG2D in leukemia. Blood 2003; 102: 1389-96.
20. Doubrovina E S, Doubrovin M M, Vider E et al. Evasion from NK cell immunity by MHC class I chain-related molecules expressing colon adenocarcinoma. J Immunol 2003; 171: 6891-9.
21. Lee J C, Lee K M, Kim D W, Heo D S. Elevated TGF-beta1 secretion and down-modulation of NKG2D underlies impaired NK cytotoxicity in cancer patients. J Immunol 2004; 172: 7335-40.
22. Ghiringhelli F, Menard C, Terme M et al. CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner. J Exp Med 2005; 202: 1075-85.
23. Japanese Society for Esophageal Disease. Guidelines for the Clinical and Pathologic Studies on Carcinoma of the Esophagus, 9th edn. Tokyo, Japan: Kanehara Press, 1999.
24. Ruggeri L, Capanni M, Urbani E et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002; 295: 2097-100.
25. Castriconi R, Dondero A, Augugliaro R et al. Identification of 4Ig-B7-H3 as a neuroblastoma-associated molecule that exerts a protective role from an NK cell-mediated lysis. Proc Natl Acad Sci USA 2004; 101: 12640-5.
26. Borg C, Terme M, Taieb J et al. Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effects. J Clin Invest 2004; 114: 379-88.
27. Wu J D, Higgins L M, Steinle A, Cosman D, Haugk K, Plymate S R. Prevalent expression of the immunostimulatory MHC class I chain-related molecule is counteracted by shedding in prostate cancer. J Clin Invest 2004; 114: 560-8.
28. Curiel T J, Coukos G, Zou L et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004; 10: 942-9.
29. Hiraoka N, Onozato K, Kosuge T, Hirohashi S. Prevalence of FOXP3+ regulatory T cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions. Clin Cancer Res 2006; 12: 5423-34.
30. Ichihara F, Kono K, Takahashi A, Kawaida H, Sugai H, Fujii H. Increased populations of regulatory T cells in peripheral blood and tumor-infiltrating lymphocytes in patients with gastric and esophageal cancers. Clin Cancer Res 2003; 9: 4404-8.
31. El Andaloussi A, Han Y, Lesniak M S. Prolongation of survival following depletion of CD4+CD25+ regulatory T cells in mice with experimental brain tumors. J Neurosurg 2006; 105: 430-7.
32. Dannull J, Su Z, Rizzieri D et al. Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J Clin Invest 2005; 115: 3623-33.